Novartis: Lymphoma study shows CART on track for 2017 U.S. submission

ZURICH (Reuters) - Swiss drugmaker Novartis said the latest findings from a study on its newest therapy for two kinds of blood cancer track earlier results, bolstering its confidence in a 2017 U.S. regulatory submission.

http://ift.tt/xePdMM

from Reuters: Health News
via animenewspro